| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0065-2571(01)00060-7 |
| P8608 | Fatcat ID | release_rdl3z7tz3jcaxp43r5atbnz7aq |
| P698 | PubMed publication ID | 12123713 |
| P50 | author | Hideaki Tsuge | Q46648414 |
| P2093 | author name string | N Katunuma | |
| M Fukushima | |||
| M Nukatsuka | |||
| P2860 | cites work | Bone loss induced by cancer treatment and its management | Q77312714 |
| Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption | Q77449793 | ||
| Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors | Q27730182 | ||
| RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 | ||
| Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein | Q36079478 | ||
| A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells | Q39100887 | ||
| Overview of bisphosphonates | Q41637516 | ||
| Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. | Q54137269 | ||
| Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization | Q57272396 | ||
| Effects of dichloromethylene diphosphonate on the osteolytic and osteoplastic effects of rat prostate adenocarcinoma cells | Q69977844 | ||
| Participation of cathepsin L on bone resorption | Q70670024 | ||
| Prolongation of survival period and improvement of cancer cachexia by long-term administration of UFT | Q71148343 | ||
| Comparative study of inhibitory effects by murine interferon ? and a new bisphosphonate (alendronate) in hypercalcemic, nude mice bearing human tumor (LJC-1-JCK) | Q71649346 | ||
| Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo | Q73077056 | ||
| Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption | Q73174502 | ||
| Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo | Q73673392 | ||
| Regulation of collagenolytic protease secretion through c-Src in osteoclasts | Q73937025 | ||
| Regulation of collagenolytic cysteine protease synthesis by estrogen in osteoclasts | Q74015246 | ||
| Distinct roles of cathepsin K and cathepsin L in osteoclastic bone resorption | Q74095795 | ||
| Effects of YM175, a new-generation bisphosphonate, on hypercalcemia induced by tumor-derived bone resorbing factors in rats | Q74441299 | ||
| Bone metastases--the clinical problem | Q77312680 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cancer metastasis | Q120912394 |
| P304 | page(s) | 159-172 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Advances in Enzyme Regulation | Q15756443 |
| P1476 | title | Structure-based development of cathepsin L inhibitors and therapeutic applications for prevention of cancer metastasis and cancer-induced osteoporosis | |
| P478 | volume | 42 |
| Q55474273 | Affinity-Enhanced Luminescent Re(I)- and Ru(II)-Based Inhibitors of the Cysteine Protease Cathepsin L. |
| Q38025001 | Cancer-associated lysosomal changes: friends or foes? |
| Q37724780 | Cathepsin L in metastatic bone disease: therapeutic implications |
| Q36218199 | Cathepsin L targeting in cancer treatment. |
| Q36650691 | Protease inhibitors and their peptidomimetic derivatives as potential drugs |
Search more.